Rosiglitazone improves contextual fear conditioning in aged rats.
Experimental, clinical, and epidemiologic studies indicate that non-steroidal anti-inflammatory drugs (NSAIDs) are beneficial in Alzheimer's disease and other neuroinflammatory processes. One possible mechanism is an interaction with peroxisome proliferator-activated receptors (PPARs). We examined the effect of a specific PPARgamma agonist, rosiglitazone, on contextual fear conditioning in aged rats. Male rats (20-months-old) were administered rosiglitazone in the diet for 2 months prior to behavioral testing. Young control and aged rats fed rosiglitazone froze significantly more than did the aged control rats in a hippocampal-dependent fear conditioning task. Rosiglitazone had no effect hippocampal interleukin-1beta levels, markers of oxidative damage, and NMDA receptor expression. Therefore, activation of PPARgamma prevented age-related deficits in hippocampal function.
Gemma
Carmelina
C
James A. Haley VA Hospital, 13000 Bruce B. Downs Blvd., Tampa, FL, 33612, USA.
Stellwagen
Heather
H
Fister
Matthew
M
Coultrap
Steven J
SJ
Mesches
Michael H
MH
Browning
Michael D
MD
Bickford
Paula C
PC
D000375:Aging / Q000187:drug effects* / Q000502:physiology / Q000523:psychology; D000818:Animals; D003213:Conditioning, Psychological / Q000187:drug effects* / Q000502:physiology; D005239:Fear / Q000187:drug effects* / Q000502:physiology / Q000523:psychology; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
D045162:Thiazolidinediones; D000077154:Rosiglitazone